scholarly journals Investigation on thermomechanical properties of poly (l-lactic acid) for the stretch blow moulding process of bioresorbable vascular scaffold

2017 ◽  
Author(s):  
Huidong Wei ◽  
Gary Menary
Keyword(s):  
Lactic Acid ◽  
Thermomechanical Properties ◽  
Bioresorbable Vascular Scaffold ◽  
Moulding Process ◽  
Blow Moulding ◽  
Vascular Scaffold

scholarly journals Modelling Stretch Blow Moulding of Poly (l-lactic acid) for the Manufacture of Bioresorbable Vascular Scaffold

Polymers ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 967
Author(s):  
Huidong Wei ◽  
Shiyong Yan ◽  
Gary Menary
Keyword(s):  
Lactic Acid ◽  
Strain History ◽  
Forming Process ◽  
Stress Strain ◽  
Bioresorbable Vascular Scaffold ◽  
Blow Moulding ◽  
Operation Conditions ◽  
Fea Model ◽  
Vascular Scaffold ◽  
Strain Relationship

Stretch blow moulding (SBM) has been employed to manufacture bioresorbable vascular scaffold (BVS) from poly (l-lactic acid) (PLLA), whilst an experience-based method is used to develop the suitable processing conditions by trial-and-error. FEA modelling can be used to predict the forming process by the scientific understanding on the mechanical behaviour of PLLA materials above the glass transition temperature (Tg). The applicability of a constitutive model, the ‘glass-rubber’ (GR) model with material parameters from biaxial stretch was examined on PLLA sheets replicating the biaxial strain history of PLLA tubes during stretch blow moulding. The different stress–strain relationship of tubes and sheets under equivalent deformation suggested the need of re-calibration of the GR model for tubes. A FEA model was developed for PLLA tubes under different operation conditions, incorporating a virtual cap and rod to capture the suppression of axial stretch. The reliability of the FEA modelling on tube blowing was validated by comparing the shape evolution, strain history and stress–strain relationship from modelling to the results from the free stretch blow test.

scholarly journals Long-term follow-up of therapeutic efficacy of everolimus-eluting bioresorbable vascular scaffold in comparison to everolimus-eluting stent in treatment of chronic total occlusion guided by intracoronary imaging

2020 ◽  
Vol 72 (1) ◽  
Author(s):  
Mohammad Abdallah Eltahlawi ◽  
Abdel-Aziz Fouad Abdel-Aziz ◽  
Abdel-Salam Sherif ◽  
Khalid Abdel-Azeem Shokry ◽  
Islam Elsayed Shehata
Keyword(s):  
Chronic Total Occlusion ◽  
Bioresorbable Vascular Scaffold ◽  
Total Occlusion ◽  
Intracoronary Imaging ◽  
Group I ◽  
Significant Difference ◽  
Vascular Scaffold ◽  
Long Term Follow Up

Abstract Background We hypothesized that 1st generation everolimus-eluting bioresorbable vascular scaffold (BVS) stent associated with less complication and less restenosis rate than everolimus-eluting stent (EES) in chronic total occlusion (CTO) recanalization guided by intracoronary imaging. Therefore, we aimed to assess the safety and performance of BVS stent in CTO revascularization in comparison to EES guided by intracoronary imaging. Our prospective comparative cross-sectional study was conducted on 60 CTO patients divided into two groups according to type of stent revascularization: group I (EES group): 40 (66.7%) patients and group II (BVS group): 20 (33.3%) patients. All patients were subjected to history taking, electrocardiogram (ECG), echocardiography, laboratory investigation, stress thallium study to assess viability before revascularization. Revascularization of viable CTO lesion guided by intracoronary imaging using optical coherence tomography (OCT). Then, long-term follow-up over 1 year clinically and by multi-slice CT coronary angiography (MSCT). Our clinical and angiographic endpoints were to detect any clinical or angiographic complications during the follow-up period. Results At 6 months angiographic follow-up, BVS group had not inferior angiographic parameters but without statistically significant difference (p = 0.566). At 12 months follow-up, there was no difference at end points between the two groups (p = 0.476). No differences were found at angiographic or clinical follow-up between BVS and EES. Conclusion This study shows that 1st generation everolimus-eluting BVS is non-inferior to EES for CTO revascularization. Further studies are needed to clearly state which new smaller footprint BVS, faster reabsorption, magnesium-based less thrombogenicity, and advanced mechanical properties is under development. We cannot dismiss the efficacy and safety of new BVS technology. Trial registration ZU-IRB#2498/3-12-2016 Registered 3 December 2016, email: [email protected]

scholarly journals Bioresorbable Vascular Scaffold Korean Expert Panel Report

2017 ◽  
Vol 47 (6) ◽  
pp. 795 ◽  
Author(s):  
Jung-Min Ahn ◽  
Duk-Woo Park ◽  
Sung Jin Hong ◽  
Young Keun Ahn ◽  
Joo-Yong Hahn ◽  
...  
Keyword(s):  
Expert Panel ◽  
Bioresorbable Vascular Scaffold ◽  
Panel Report ◽  
Vascular Scaffold

Clinical Use of Everolimus-eluting Bioresorbable Vascular Scaffold (BVS) In Treating Coronary Artery Disease

2013 ◽  
Vol 111 (7) ◽  
pp. 23B
Author(s):  
Michael Liang ◽  
Takashi Kajiya ◽  
Chi-Hang Lee ◽  
Mark Chan ◽  
Swee-Guan Teo ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Clinical Use ◽  
Bioresorbable Vascular Scaffold ◽  
Vascular Scaffold ◽  
Artery Disease

Bioresorbable vascular scaffold implantation to bail out nail gun injury in ST-segment myocardial infarction

2017 ◽  
Vol 107 (1) ◽  
pp. 87-90
Author(s):  
Torsten Schütz ◽  
Friedrich P. Krönig ◽  
Christoph Karmeinsky ◽  
Oliver Weingärtner
Keyword(s):  
Myocardial Infarction ◽  
Bioresorbable Vascular Scaffold ◽  
St Segment ◽  
Vascular Scaffold ◽  
Bail Out ◽  
Nail Gun Injury
Sign in / Sign up

Export Citation Format

Share Document